Lucid Diagnostics (LUCD) Expected to Announce Earnings on Monday

Lucid Diagnostics (NASDAQ:LUCD) is expected to post its quarterly earnings results before the market opens on Monday, March 24th. Analysts expect Lucid Diagnostics to post earnings of ($0.15) per share and revenue of $1.42 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Lucid Diagnostics Stock Down 3.2 %

Shares of NASDAQ LUCD opened at $1.52 on Friday. The stock has a market cap of $90.20 million, a P/E ratio of -1.33 and a beta of 1.34. Lucid Diagnostics has a fifty-two week low of $0.63 and a fifty-two week high of $1.63. The firm’s 50-day simple moving average is $1.20 and its 200 day simple moving average is $0.98.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets reduced their target price on Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating for the company in a report on Monday, December 9th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Lucid Diagnostics has a consensus rating of “Buy” and a consensus price target of $3.63.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.